NeuroSense Therapeutics (NRSN) Total Non-Current Liabilities (2021 - 2025)
NeuroSense Therapeutics (NRSN) posted Total Non-Current Liabilities of $72000.0 for Q4 2025, up 100.0% sequentially from $36000.0 in Q2 2024.
NeuroSense Therapeutics (NRSN) Total Non-Current Liabilities (2021 - 2025) Analysis & Trends
NeuroSense Therapeutics has reported Total Non-Current Liabilities for 5 years, with the latest figure at $72000.0 in Q4 2025.
- Quarterly Total Non-Current Liabilities changed N/A year-over-year to $72000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $72000.0 (changed N/A YoY) and the FY2025 annual result came in at $72000.0, changed N/A from the prior year.
- Total Non-Current Liabilities grew to $72000.0 in Q4 2025 per NRSN's latest filing, from $36000.0 in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $6.4 billion in Q2 2023 and troughed at $36000.0 in Q2 2024.
- A 5-year average of $583.8 million and a median of $1.4 million in 2022 frame the typical range for Total Non-Current Liabilities.
- The sharpest annual moves came in 2023 and 2024: Total Non-Current Liabilities surged 727255.28% in 2023, then sank 100.0% in 2024.
- Over 5 years, Total Non-Current Liabilities stood at $1.8 million in 2021, then sank by 91.96% to $147000.0 in 2022, then soared by 910.2% to $1.5 million in 2023, then sank by 97.58% to $36000.0 in 2024, then surged by 100.0% to $72000.0 in 2025.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $72000.0, $36000.0, and $4.6 million for Q4 2025, Q2 2024, and Q1 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.32 Bn |
| 10 | NeuroSense Therapeutics | 9.68 Mn | 9.47 Mn | - | 72,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 72,000.00 |
| Jun 30, 2024 | 36,000.00 |
| Mar 31, 2024 | 4.59 Mn |
| Dec 31, 2023 | 1.49 Mn |
| Jun 30, 2023 | 6.41 Bn |
| Mar 31, 2023 | 1.92 Mn |
| Dec 31, 2022 | 147,000.00 |
| Sep 30, 2022 | 984,000.00 |
| Jun 30, 2022 | 881,000.00 |
| Mar 31, 2022 | 1.44 Mn |
| Dec 31, 2021 | 1.83 Mn |